Microbot Medical Inc Dossier
Qualitative Analysis
Business overview
Microbot Medical Inc. (NASDAQ: MBOT) is a clinical-to-commercial stage medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery (MIS) space. The company's primary focus is its proprietary LIBERTY® Endovascular Robotic Surgical System, which is designed as the world's first single-use, fully disposable, remotely operated robotic solution for peripheral endovascular procedures. By utilizing a disposable, single-use model, the LIBERTY system aims to eliminate the high capital costs, sterilization requirements, and heavy footprint associated with traditional multi-million dollar surgical robots, while simultaneously reducing radiation exposure and physical strain for interventional operators.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Transitioning from a research and development stage to a commercial-stage enterprise by executing the Full Market Release (FMR) of the LIBERTY Endovascular Robotic System in the U.S., targeting a market of 2.5 million annual peripheral endovascular procedures.
Expected impact: Establishment of a robust sales, marketing, and product distribution infrastructure to drive hospital adoption across key states.
Partnering with Lovell Government Services to serve federal healthcare systems, listing the LIBERTY System on major federal procurement platforms such as GSA Advantage, ECAT, and DAPA.
Expected impact: Streamlined sales process and direct access to over 2,000 government facilities, including the Veterans Health Administration (VHA) and Military Health System (MHS).
Establishing commercial readiness and sales strategies in international markets, starting with Israel and working toward CE Mark certification in Europe.
Expected impact: Access to the European market representing approximately 2.3 million annual peripheral endovascular procedures.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Serves as Microbot's Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor to facilitate access to federal contracting frameworks and expand the LIBERTY System's reach to over 2,000 government facilities.
Terms: Financial terms of the agreement were not disclosed.
Emory became the first hospital to adopt the LIBERTY system for patient care. The collaboration aims to establish an Endovascular Robotics Program in interventional radiology and explore integrating the system with imaging platforms.
Terms: Feasibility and integration program responsibilities assumed by Emory University.